1. Home
  2. FLOC vs DNLI Comparison

FLOC vs DNLI Comparison

Compare FLOC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLOC
  • DNLI
  • Stock Information
  • Founded
  • FLOC 1996
  • DNLI 2013
  • Country
  • FLOC United States
  • DNLI United States
  • Employees
  • FLOC N/A
  • DNLI N/A
  • Industry
  • FLOC Metal Fabrications
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FLOC Industrials
  • DNLI Health Care
  • Exchange
  • FLOC Nasdaq
  • DNLI Nasdaq
  • Market Cap
  • FLOC 2.6B
  • DNLI 3.1B
  • IPO Year
  • FLOC 2025
  • DNLI 2017
  • Fundamental
  • Price
  • FLOC $26.93
  • DNLI $20.73
  • Analyst Decision
  • FLOC Strong Buy
  • DNLI Strong Buy
  • Analyst Count
  • FLOC 4
  • DNLI 13
  • Target Price
  • FLOC $33.50
  • DNLI $37.91
  • AVG Volume (30 Days)
  • FLOC 318.3K
  • DNLI 836.0K
  • Earning Date
  • FLOC 01-01-0001
  • DNLI 03-04-2025
  • Dividend Yield
  • FLOC N/A
  • DNLI N/A
  • EPS Growth
  • FLOC N/A
  • DNLI N/A
  • EPS
  • FLOC 7.60
  • DNLI N/A
  • Revenue
  • FLOC $424,747,000.00
  • DNLI N/A
  • Revenue This Year
  • FLOC N/A
  • DNLI N/A
  • Revenue Next Year
  • FLOC N/A
  • DNLI $289.18
  • P/E Ratio
  • FLOC $3.55
  • DNLI N/A
  • Revenue Growth
  • FLOC 185.82
  • DNLI 204.74
  • 52 Week Low
  • FLOC $25.62
  • DNLI $14.56
  • 52 Week High
  • FLOC $30.50
  • DNLI $33.33
  • Technical
  • Relative Strength Index (RSI)
  • FLOC N/A
  • DNLI 42.56
  • Support Level
  • FLOC N/A
  • DNLI $21.33
  • Resistance Level
  • FLOC N/A
  • DNLI $22.81
  • Average True Range (ATR)
  • FLOC 0.00
  • DNLI 1.27
  • MACD
  • FLOC 0.00
  • DNLI -0.10
  • Stochastic Oscillator
  • FLOC 0.00
  • DNLI 15.83

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Share on Social Networks: